# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 2121-2130 of 2220 results.
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
Status: Terminated
Last Changed: Jun 02, 2014
First Received: Aug 17, 2006
Disease(s): Anaplastic Large Cell Lymphoma
Intervention(s): Cyclophosphamide, Doxorubicin hydrochloride, vincristine sulfate, prednisone, SGN-30
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Terminated
Last Changed: Jul 02, 2013
First Received: Sep 15, 2006
Disease(s): B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
Intervention(s): alvocidib, pharmacological study, laboratory biomarker analysis
Locations: Ohio State University Medical Center, Columbus, Ohio, United States
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Recruiting
Last Changed: Aug 14, 2020
First Received: Dec 27, 2017
Disease(s): Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention(s): Daratumumab, Vincristine, Prednisone, Doxorubicin, Peg-asparaginase, Cyclophosphamide, Cytarabine, 6-mercaptopurine, Methotrexate
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Phoenix Children's Hospital, Phoenix, Arizona, United States
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
Children's Hospital Orange County, Orange, California, United States
Stanford University, Palo Alto, California, United States
... and 53 other locations.
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
Status: Completed
Last Changed: Dec 18, 2014
First Received: Feb 15, 2005
Disease(s): Non-Hodgkin Lymphoma
Intervention(s): SGN-40 (anti-huCD40 mAb)
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Stanford University, Stanford, California, United States
University of Miami, Miami, Florida, United States
Cornell University, New York, New York, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
... and 1 other locations.
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Status: Recruiting
Last Changed: Jul 08, 2020
First Received: Mar 23, 2017
Disease(s): B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
Intervention(s): Cirmtuzumab, Ibrutinib, Cirmtuzumab plus ibrutinib
Locations: City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
UCSD Moores Cancer Center, La Jolla, California, United States
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
Yale Cancer Center, New Haven, Connecticut, United States
Lousiana State University Health New Orleans (NCI Community Oncology Research Program), New Orleans, Louisiana, United States
... and 8 other locations.
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin´s Lymphoma (NHL)
Status: Active, not recruiting
Last Changed: Dec 11, 2019
First Received: Sep 13, 2012
Disease(s): Non-Hodgkin Lymphoma
Intervention(s): MOR00208 (formerly Xmab 5574)
Locations: MorphoSys Research Site, Norwalk, Connecticut, United States
MorphoSys Research Site, Hackensack, New Jersey, United States
Morphosys Research Site, Columbus, Ohio, United States
Morphosys Research Site, Lubbock, Texas, United States
MorphoSys Research Site, Brussels #1, Belgium
... and 22 other locations.
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
Status: Active, not recruiting
Last Changed: Jul 28, 2020
First Received: Dec 19, 2018
Disease(s): Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Intervention(s): Rituximab, Fludarabine, Cyclophosphamide, MG4101(allogeneic Natural Killer cell), Interleukin-2
Locations: Asan Medical Center, Seoul, Korea, Republic of
Samsung Medical Center, Seoul, Korea, Republic of
Seoul National Univ. Hospital, Seoul, Korea, Republic of
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Recruiting
Last Changed: Aug 28, 2020
First Received: Nov 06, 2017
Disease(s): Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Intervention(s): JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
City of Hope, Duarte, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
University of California, Los Angeles, Los Angeles, California, United States
... and 30 other locations.
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Status: Active, not recruiting
Last Changed: Feb 10, 2020
First Received: May 01, 2012
Disease(s): Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia
Intervention(s): ibrutinib, Correlative laboratory samples, quality of life assessment
Locations: Ohio State University Medical Center, Columbus, Ohio, United States
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
Status: Recruiting
Last Changed: Jan 13, 2020
First Received: Feb 07, 2018
Disease(s): Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
Intervention(s): Ibrutinib
Locations: DUMMY, Dummy, France